# Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

> **NCT03500562** · — · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 3 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03500562
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-08
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-03-29
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Insufficient Enrollment
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500562, "Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03500562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*